Management just needs to sell one of their assets
Post# of 30028
Eventually, they can buy more assets and progress things forward. In my knowledge of biotech investing; the Scientific data is whats its all about...the question is Mgt. trying to mature assets and transact later down the road (which I think is a dangerous concept....if market conditions continue to improve it just might open up some new investor interest willing to take on more risk.
Time will tell!!